An Introduction to Diabetes
Diabetes is an enormous health burden worldwide, and the current epidemic of type 2 diabetes is of paramount concern. The most important recent advances in the management of type 1 diabetes have been immunotherapies, designed to delay disease onset and the development of fully automated artificial pancreas systems that integrate blood glucose monitoring and insulin delivery. In type 2 diabetes, the widespread use of DPP-4 inhibitors, GLP-1 receptor agonists and SGLT-2 inhibitors have facilitated optimal glycaemic control without increased risk of hypoglycaemia and weight gain. Emerging data from cardiovascular outcome trials have shown that these agents can reduce the risk of cardiovascular disease in high-risk individuals.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Our supporting partners do not constitute an endorsement of the content on this page.
Welcome to the IDF Virtual Congress 2021
Programme Chair Prof. João Filipe Raposo introduces the programme for the International Diabetes Federation (IDF) Virtual Congress 2021 (December 6-11) focusing on diabetes complications and the links between COVID-19 and diabetes. https://www.idf2021.org
The DFUC 2020 Dataset: Analysis Towards Diabetic Foot Ulcer Detection
touchREVIEWS in Endocrinology. 2021;17(1):5–11 DOI: https://doi.org/10.17925/EE.2021.17.1.5
Wounds on the feet, known as diabetic foot ulcers (DFUs), are a major complication of diabetes. DFUs can become infected, leading to amputation of the foot or lower limb. Patients who undergo amputation experience significantly reduced survival rates.1 In previous studies, researchers have achieved high accuracy in the recognition of DFUs using machine learning algorithms.2–5 […]
Diabetes Mellitus of Pituitary Origin: A Case Report
touchREVIEWS in Endocrinology. 2021;17(1):68–70 DOI: https://doi.org/10.17925/EE.2021.17.1.68
Acromegaly is a chronic, progressive disease characterized by an excess secretion of growth hormone, and consequently, increased circulating insulin-like growth factor 1 (IGF-1) levels. These patients typically exhibit acral and soft tissue overgrowth, headache, arthritis and visual disturbances. Impaired glucose tolerance and diabetes mellitus are also frequently associated with acromegaly.1 We describe a patient who […]
Matthew Budoff, ENDO 2021: Findings from a Substudy of the VERTIS CV Trial – Ertugliflozin for T2DM & ASCVD
We caught up with Professor Matthew Budoff (UCLA and Lundquist Institute, Torrance, CA, US) to discuss ertugliflozin in patients with type 2 diabetes mellitus and established atherosclerotic cardiovascular disease inadequately controlled with metformin and sulfonylurea (Clinical Trial Identifier: NCT01986881). ‘Efficacy and Safety of Ertugliflozin in Patients With Type 2 Diabetes Mellitus and Established Cardiovascular Disease […]
Dapagliflozin as an Adjunct Therapy to Insulin in Patients with Type 1 Diabetes Mellitus: Efficacy and Safety of this Combination
touchREVIEWS in Endocrinology. 2021;17(1):12-20 DOI: https://doi.org/10.17925/EE.2021.17.1.12
The prevalence of diabetes type 1 (T1D) and type 2 (T2D) is increasing worldwide; the number of people with diabetes was 463 million in 2019, but it is estimated to reach 700 million by 2045.1 The incidence of T1D is increasing in most countries.1 Age- and sex-standardized incidence rates from 1998 to 2013 (up to 25 years) […]
The Role of Individualized Exercise Prescription in Type 2 Diabetes Mellitus Management
touchREVIEWS in Endocrinology. 2021;17(1):2–4 DOI: https://doi.org/10.17925/EE.2021.17.1.2
Diabetes mellitus is a chronic disease that affects many people around the world. Sedentary lifestyle is considered a main risk factor for type 2 diabetes mellitus (T2DM). As presented in this editorial, the advantages of activity in preventing and treating T2DM are widely recognized. Exercise training improves glycaemic control, body composition, cardiorespiratory wellness, physical functioning […]
Insulin at 100: a life-saving discovery but more remains to be done
2021 marks the centenary of the discovery of insulin. It is important to remind ourselves that this life-saving medication still remains beyond the reach of many people with diabetes who need it. Find out more at: https://worlddiabetesday.org/about/insulin-at-100/ Support: Published in collaboration with the International Diabetes Federation.
Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists
US Endocrinology. 2020;16(2):80–7 DOI: https://doi.org/10.17925/USE.2020.16.2.80
In the USA, over 30 million people—about 10% of the population—have diabetes.1 Worldwide, the number of people with diabetes has risen sharply, especially in low- and middle-income countries. One in 11 adults—about 470 million people—had diabetes in the year 2019, and 700 million cases are projected worldwide by 2045.2 The vast majority of people with diabetes, >95%, […]
Chronic kidney disease in patients with type 2 diabetes: What is the place for mineralocorticoid receptor antagonists?
Watch interviews with three internationally recognized experts about the role of mineralocorticoid receptor antagonists in the treatment and prevention of chronic kidney disease in patients with type 2 diabetes.
- Describe novel approaches to targeting inflammation and fibrosis for the treatment of chronic kidney disease in type 2 diabetes
- Describe the rationale for targeting the mineralocorticoid receptor for the treatment of chronic kidney disease in type 2 diabetes
- Discuss clinical trial data for novel mineralocorticoid receptor antagonists for the treatment of chronic kidney disease in patients with type 2 diabetes
Journal articles and more to your inbox
Get the latest clinical insights from touchENDOCRINOLOGYSign me up!